Oncolytic viruses: Therapeutic smart bombs

Jonathan Brammer, Ken S. Rosenthal

Research output: Contribution to journalArticle

Abstract

Oncolytic virus therapy has been used for more than 50 years capitalizing on the properties of viruses to selectively kill or deliver genes to tumor cells. Viruses target tumor cells because the cells are growing and provide the biochemical machinery to facilitate virus replication, and many have deregulated the control measures that would impede a virus. These conditions allow viruses that are usually benign or lacking accessory genes for growth in normal cells to become oncolytic with selectivity for growth and killing of tumor cells. Reovirus, paramyxoviruses, adenovirus lacking the E1a or E1b genes, or herpes simplex virus lacking the ICP34.5 or ribonucleotide reductase become smart bombs that can seek out, target, and selectively destroy tumor cells. Alternatively, these and other viruses can carry genetic payloads for enzymes or immunological proteins to mark tumor cells for killing by drugs or host responses.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalInfectious Diseases in Clinical Practice
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Oncolytic Viruses
Bombs
Viruses
Therapeutics
Neoplasms
Oncolytic Virotherapy
Genes
Ribonucleotide Reductases
Oncogenic Viruses
Simplexvirus
Virus Replication
Growth
Adenoviridae
Enzymes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Oncolytic viruses : Therapeutic smart bombs. / Brammer, Jonathan; Rosenthal, Ken S.

In: Infectious Diseases in Clinical Practice, Vol. 17, No. 1, 01.01.2009, p. 39-43.

Research output: Contribution to journalArticle

Brammer, Jonathan ; Rosenthal, Ken S. / Oncolytic viruses : Therapeutic smart bombs. In: Infectious Diseases in Clinical Practice. 2009 ; Vol. 17, No. 1. pp. 39-43.
@article{e0f8452051fa410fb198f9cc1ab2f4c0,
title = "Oncolytic viruses: Therapeutic smart bombs",
abstract = "Oncolytic virus therapy has been used for more than 50 years capitalizing on the properties of viruses to selectively kill or deliver genes to tumor cells. Viruses target tumor cells because the cells are growing and provide the biochemical machinery to facilitate virus replication, and many have deregulated the control measures that would impede a virus. These conditions allow viruses that are usually benign or lacking accessory genes for growth in normal cells to become oncolytic with selectivity for growth and killing of tumor cells. Reovirus, paramyxoviruses, adenovirus lacking the E1a or E1b genes, or herpes simplex virus lacking the ICP34.5 or ribonucleotide reductase become smart bombs that can seek out, target, and selectively destroy tumor cells. Alternatively, these and other viruses can carry genetic payloads for enzymes or immunological proteins to mark tumor cells for killing by drugs or host responses.",
author = "Jonathan Brammer and Rosenthal, {Ken S.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1097/IPC.0b013e31818d1b02",
language = "English (US)",
volume = "17",
pages = "39--43",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Oncolytic viruses

T2 - Therapeutic smart bombs

AU - Brammer, Jonathan

AU - Rosenthal, Ken S.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Oncolytic virus therapy has been used for more than 50 years capitalizing on the properties of viruses to selectively kill or deliver genes to tumor cells. Viruses target tumor cells because the cells are growing and provide the biochemical machinery to facilitate virus replication, and many have deregulated the control measures that would impede a virus. These conditions allow viruses that are usually benign or lacking accessory genes for growth in normal cells to become oncolytic with selectivity for growth and killing of tumor cells. Reovirus, paramyxoviruses, adenovirus lacking the E1a or E1b genes, or herpes simplex virus lacking the ICP34.5 or ribonucleotide reductase become smart bombs that can seek out, target, and selectively destroy tumor cells. Alternatively, these and other viruses can carry genetic payloads for enzymes or immunological proteins to mark tumor cells for killing by drugs or host responses.

AB - Oncolytic virus therapy has been used for more than 50 years capitalizing on the properties of viruses to selectively kill or deliver genes to tumor cells. Viruses target tumor cells because the cells are growing and provide the biochemical machinery to facilitate virus replication, and many have deregulated the control measures that would impede a virus. These conditions allow viruses that are usually benign or lacking accessory genes for growth in normal cells to become oncolytic with selectivity for growth and killing of tumor cells. Reovirus, paramyxoviruses, adenovirus lacking the E1a or E1b genes, or herpes simplex virus lacking the ICP34.5 or ribonucleotide reductase become smart bombs that can seek out, target, and selectively destroy tumor cells. Alternatively, these and other viruses can carry genetic payloads for enzymes or immunological proteins to mark tumor cells for killing by drugs or host responses.

UR - http://www.scopus.com/inward/record.url?scp=68049095157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049095157&partnerID=8YFLogxK

U2 - 10.1097/IPC.0b013e31818d1b02

DO - 10.1097/IPC.0b013e31818d1b02

M3 - Article

AN - SCOPUS:68049095157

VL - 17

SP - 39

EP - 43

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 1

ER -